On December 16, Zhejiang Daoer Biotechnology Co.
, Ltd.
announced that it has reached a clinical trial cooperation agreement with Merck to explore the clinical trial
of Doyle Biologics anti-Claudin18.
2 antibody DR30303 and Merck's PD-1 inhibitor KEYTRUDA® (pembrolizumab) in the treatment of gastric cancer or gastroesophageal junction cancer.
Under this agreement, Doyle Biologics will conduct a clinical trial based on mutually agreed and finalized clinical protocols to evaluate the safety and efficacy
of DR30303 in combination with KEYTRUDA® in patients with Claudin18.
2-positive, locally advanced unresectable or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ).
In fact, since the beginning of this year, the cooperation between multinational pharmaceutical companies and local innovative pharmaceutical companies and third-party commercialization platforms has been reported in the industry
.
For example, some time ago, AstraZeneca signed a strategic cooperation agreement
with BAHEAL Pharmaceutical.
According to the agreement, BAHEAL Pharmaceutical will obtain the commercial operation rights
of AstraZeneca's hypoglycemic drug Anritze (saxagliptin tablets).
The two parties hope that through this cooperation, access to drugs will be further improved, so that classic antidiabetic drugs can benefit more hospitals and patients
.
Regarding the hand-in-hand with BAHEAL Pharmaceutical, the relevant person in charge of AstraZeneca China said: "Anritzer has entered the Chinese market for more than ten years and is a classic oral diabetes drug
.
Based on BAHEAL Pharmaceutical's rich experience in cooperation with multinational enterprises, we believe that this alliance will be a win-win cooperation, and hope that the two parties will work closely together on the basis of mutual trust to explore innovative business cooperation models and maximize the long-term value
of the Anritzer brand.
" ”
Prior to this, Innovent Biologics announced that it had also reached a multi-project strategic cooperation and licensing agreement with Sanofi to cooperate in the development of two high-potential anti-tumor drugs SAR408701 (Tusamitamab Ravtansine; Clinical development and commercialization of anti-CEACAM5 antibody-drug conjugate) and SAR444245 (non-α-biased IL-2) in China, including exploring a series of clinical studies in combination with PD-1 inhibitor dab ® (Cindilimab injection), aiming to accelerate the development and market access of innovative therapies for the benefit of cancer patients
in China.
In September, Simcere Pharma and Almirall, a long-established European pharmaceutical company, jointly announced that they had reached a licensing agreement for a preclinical autoimmune disease innovative drug developed by Simcere, Almirall obtained the exclusive rights to develop and commercialize the drug outside Greater China, and Simcere Pharmaceutical will receive a total milestone payment of up to US$492 million, including US$15 million down payment
.
.
.
.
.
.
.
From the current point of view, in order to strengthen and expand the R&D pipeline and accelerate the commercialization of products, the cooperation between domestic and foreign pharmaceutical companies is becoming more and more frequent, and the cooperation content has also involved many aspects
such as products and marketing.
Among them, it is worth noting that the development of new drugs is obviously still the focus
of corporate cooperation.
In this regard, analysts believe that these cooperative enterprises will achieve a win-win situation in the future, and usher in more new opportunities
while promoting more and more new drugs to accelerate the market.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
